Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Cytodyme
AddedJun 25, 2026
UpdatedJul 6, 2026
Cytodyme

Cytodyme

Pre-Seed

Cytodyme builds software that automates post-market surveillance and regulatory compliance workflows for medical device companies.

HQ
San Diego, CA, US
Overview
Compare
Fundraising
Employees

Cytodyme provides medtech companies with a connected platform for post-market activities including complaint management, investigations, vigilance, and literature surveillance. The system is designed to support MDR, IVDR, and FDA 21 CFR Part 11 compliance with structured records and end-to-end audit trails.

The platform connects post-market data, supporting evidence, and decisions to generate audit-ready reports such as PSUR, PMPF, and CER documents. It monitors regulatory updates across regions and surfaces which products and reports are impacted.

Cytodyme - Similar Companies

Panoptive logo

Panoptive

panoptive.com

Adentris logo

Adentris

adentris.com

Complir logo

Complir

complir.io

Mechadoc logo

Mechadoc

mechadoc.io

Readily logo

Readily

readily.co

smarteeva logo

smarteeva

smarteeva.com

Panacea logo

Panacea

withpanacea.com

CodaHx logo

CodaHx

codahx.com

Cardamon logo

Cardamon

cardamon.ai

Parachute logo

Parachute

parachute-ai.com

Odysseus Health AI logo

Odysseus Health AI

Corelayer logo

Corelayer

corelayer.com

Regbase logo

Regbase

regbase.com

Essenvia logo

Essenvia

essenvia.com

CellType logo

CellType

celltype.com

Cytodyme - Quick Facts

Who are Cytodyme's competitors?

Companies similar to Cytodyme include Panoptive, Adentris, Complir and Mechadoc.

Where is Cytodyme's headquarters located?

Cytodyme's headquarters is located in San Diego, CA, US.

When was Cytodyme's last funding round?

Cytodyme's most recent funding round was for $20k (USD) in January 2025.

How much has Cytodyme raised to-date?

As of Jan 1, 2025, Cytodyme has raised a total of $20k (USD).

Cytodyme - Classification

Industry
  • Healthcare SaaS